Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966030 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9CTSKHPGD | |
| SCHEMBL82202 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9CTSKHPGD | |
| SCHEMBL2896482 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL240005 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL1357066 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL6213019 | 0.91 | HSD17B10 (0.52) | DPP4DPP8DPP9CTSK | |
| SCHEMBL6166916 | 0.89 | CTSK (0.49) | DPP4DPP8DPP9CTSK | |
| SCHEMBL16067363 | 0.89 | CTSK (0.49) | DPP4DPP8DPP9CTSK | |
| SCHEMBL7380781 | 0.86 | HPGD (0.48) | CTSKHPGDPREP | |
| SCHEMBL9555116 | 0.86 | HPGD (0.48) | CTSKHPGDPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | ALBIUS SCIENCES ALPHA PRIVATE LIMITED (SG) | 2024-10-03 | — | — | US | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2022270628-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | 国立大学法人 大分大学 | 2022-12-29 | — | — | WO | disclosed |
| EP-3052497-B1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | WOCKHARDT LTD (IN) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | RSU1, TSLP, HAVCR2 | DPP4 137/4885DPP8 794/4885DPP9 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.